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New disinfection methods include a persistent antimicrobial coating that can be applied to inanimate
and animate objects (Surfacine), a high-level disinfectant with reduced exposure time (ortho-
phthalaldehyde), and an antimicrobial agent that can be applied to animate and inanimate objects
(superoxidized water). New sterilization methods include a chemical sterilization process for endoscopes
that integrates cleaning (Endoclens), a rapid (4-hour) readout biological indicator for ethylene oxide
sterilization (Attest), and a hydrogen peroxide plasma sterilizer that has a shorter cycle time and improved
efficacy (Sterrad 50).
Table 1. New methods in disinfection and sterilization
Process            Agent  Regulatory agency action
Disinfection Ortho-phthalaldehyde FDA cleared, October 1999
  (Cidex OPA)
Antimicrobial coating Not FDA/EPA cleared
  (Surfacine)
Superoxidized water Not FDA/EPA cleared
  (Sterilox)
Sterilization Liquid sterilization Not FDA cleared
   process (Endoclens)
Rapid readout ethylene Not FDA cleared
  oxide biological
  indicator (Attest)
New plasma sterilizer FDA cleared, Jan 1999
  (Sterrad 50)
Table 2. Activity of glutaraldehyde and ortho-phthalaldehyde against
Mycobacterium bovis
Disinfectant Time for 6-log10 reductiona
1.5% glutaraldehyde 28-36 minutes
2.5% glutaraldehyde 14-18 minutes
0.21% ortho-phthalaldehyde 4.8-6.3 minutes
aRange of values from two different laboratories (4).
The need for appropriate disinfection procedures is
highlighted by the multitude of outbreaks resulting from
improperly decontaminated patient-care items. Because
sterilizing all such items is unnecessary, hospital policies
need to identify whether cleaning, disinfection, or steriliza-
tion is indicated based primarily on an item’s intended use
but considering other factors including cost. We review new
methods of disinfection and sterilization. Criteria for
inclusion were technologies cleared in 1999 or 2000 by the
Food and Drug Administration (FDA) or submitted to the
FDA or Environmental Protection Agency (EPA) but not yet
cleared (Table 1). These technologies have the potential to
improve patient care, but in general their antimicrobial
activity has not been independently validated.
Rational Approach to Disinfection and Sterilization
More than 25 years ago, Spaulding devised an approach
to disinfection and sterilization of patient-care items or
equipment that has proved to be so clear and logical that it
has been retained, refined, and successfully used by infection
control professionals (1). Spaulding believed that how an
object should be disinfected depended on its intended use. The
three categories he described were critical, semicritical, and
noncritical. Critical objects (those that enter sterile tissues or
the vascular system or through which blood flows, such as
implanted medical devices) should be sterile when used.
Semicritical items (that touch mucous membranes or
nonintact skin, e.g., endoscopes, respiratory therapy
equipment, and diaphragms) require high-level disinfection
(i.e., elimination of all microorganisms except high numbers
of bacterial spores). Noncritical items (bedpans, blood
pressure cuffs, and bedside tables) require only low-level
disinfection.
Ortho-phthalaldehyde: A New Chemical Sterilant
Ortho-phthalaldehyde (OPA) received clearance by FDA
in October 1999. OPA solution is a clear, pale-blue liquid (pH
7.5), which typically contains 0.55% OPA. OPA has
demonstrated excellent microbiocidal activity in in vitro
studies (2,3). For example, it has shown superior
mycobactericidal activity (5-log10 reduction in 5 minutes)
compared with glutaraldehyde. The mean time required to
effect a 6-log10 reduction for M. bovis using 0.21% OPA was 6
minutes, compared with 32 minutes using 1.5% glutaralde-
hyde (Table 2) (4). When tested against a wide range of
microorganisms, including glutaraldehyde-resistant myco-
bacteria and Bacillus subtilis spores (5), OPA showed good
activity against the mycobacteria tested, including the
glutaraldehyde-resistant strains, but 0.5% OPA was not
sporicidal within 270 minutes of exposure. Increasing the pH
from its unadjusted level (about 6.5) to pH 8 improved
sporicidal activity.
OPA has several potential advantages compared with
glutaraldehyde. It requires no activation, is not a known
irritant to the eyes and nasal passages, has excellent stability
over a wide range of pH (pH 3-9), does not require exposure
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Table 3. Effect on vancomycin-resistant Enterococcus (VRE) survival of
wiping Surfacine on a treated surface over an extended period
Surface    Intervention     Day 1     Day 6     Day 13
Formica        Control 50 95 120
       Treated   0 (100%)a   0 (100%)    0 (100%)
Treated & wiped   0 (100%)   0 (100%)    0 (100%)
aPercent reduction of VRE counts per Rodac plate ([treated/control] x
100) (11).
glutaraldehyde, OPA has excellent material compatibility. A
potential disadvantage is that OPA stains proteins gray
(including unprotected skin) and thus must be handled with
caution (i.e., use of gloves, eye protection, fluid-resistant
gowns when handling contaminated instruments, contami-
nated equipment, and chemicals) (2,3). Limited clinical
studies of OPA are available. In one clinical-use study of 100
endoscopes exposed for 5 minutes to OPA, a > 5-log10
reduction in bacterial load occurred, and OPA was effective
over a 14-day usage cycle (6). Manufacturer’s data show that
OPA will last longer before reaching its minimum effective
concentration limit (about 82 cycles) compared with
glutaraldehyde (after 40 cycles) in an automatic endoscope
reprocessor (7). Disposal must be in accordance with local and
state regulations. If OPA disposal in the sanitary sewer is
restricted, glycine (25 g/gallon) can be used to neutralize the
OPA and make it safe for disposal.
The high-level disinfectant label claims for OPA solution
at 20oC vary: 5 minutes in Europe, Asia, and Latin America;
10 minutes in Canada; and 12 minutes in the United States.
FDA clearance was based on a “simulated-use” test
requirement for a 6-log10 reduction of resistant bacteria
suspended in organic matter and dried onto an endoscope.
Since this test does not include cleaning, an essential
component of disinfection of reusable devices (e.g.,
endoscopes), it is likely that the time required for high-level
disinfection of a medical device by OPA would be less than
12 minutes. Efficacy test results using mycobacteria support
a 5-minute exposure time at room temperature for OPA with
a greater than 5-log10 reduction. Canadian regulatory
authorities require a 6-log10 reduction in mycobacteria (this
requires approximately 6 min) and allow only 5-minute exposure
time intervals; thus, the exposure time for Canadians was set at
10 minutes (CG Roberts, pers. commun., Feb 2000).
Surfacine: A  New Antimicrobial Agent
Contaminated environmental surfaces have been
associated with transmission of certain nosocomial patho-
gens, principally vancomycin-resistant Enterococcus  spp.
(VRE), methicillin-resistant Staphylococcus aureus (MRSA),
and  Clostridium difficile. The incidence of nosocomial
infections caused by VRE in particular has dramatically
increased in the past decade.  Cross-transmission is thought
to result from transient hand carriage by hospital personnel,
who may potentially be colonized directly from contact with
colonized or infected patients or indirectly by contact with a
contaminated environmental surface. Cultures of surfaces in
rooms of patients colonized or infected with VRE have yielded
positive cultures in 7% to 37% of samples. Molecular analysis
of VRE strains involved in outbreaks has in some cases
demonstrated that isolates obtained from the environment
were identical to the outbreak strain (8).
Antibiotic-resistant pathogens such as VRE and MRSA
possess similar susceptibility to disinfectants as antibiotic-
susceptible strains (9,10). However, commonly used surface
disinfectants such as phenols and quaternary ammonium
compounds, while effective in eliminating these pathogens, do
not have residual activity.  Hence, after disinfection, surfaces
may rapidly be recontaminated.
Surfacine is a new, persistent antimicrobial agent that
may be used on animate or inanimate surfaces. It
incorporates a water-insoluble antimicrobial compound
(silver iodide) in a surface-immobilized coating (a modified
polyhexamethylenebiguanide) that is capable of chemical
recognition and interaction with the lipid bilayer of the
bacterial outer cell membrane by electrostatic attraction. The
intimate microbial contact with the surface results in transfer
of the antimicrobial component (silver) directly from the
coating to the organism. Microorganisms contacting the
coating accumulate silver until the toxicity threshold is
exceeded; dead microorganisms eventually lyse and detach
from the surface. The amount of silver present and the
number of microorganisms in contact with the treated surface
determine how long the coating is effective. Preliminary
studies show that treated surfaces result in excellent
elimination of antibiotic-resistant bacteria (e.g., VRE)
inoculated directly on various surfaces at challenge levels of
100 CFU/sq inch for at least 13 days (Table 3) (11).
Antimicrobial activity is retained when the surface is
subjected to repeated dry wiping or wiping with a quaternary
ammonium compound. Data available from the manufacturer
demonstrate inactivation of bacteria, yeast, fungi, and
viruses when the product is applied at challenge levels of up to
106 CFU/mL. Sustained antimicrobial activity has been
shown for the tested microorganisms. Inactivation times for
microorganisms vary.
This persistent antimicrobial agent transfers the active
biocide (silver) “on demand” directly to the organism without
elution of silver ions into solution. The coating, therefore,
functions in a chemically intelligent way, i.e., antimicrobial
response is triggered only upon microbial contact. The
mechanism of silver release differs from that of conventional,
topically applied silver compounds (e.g., silver nitrate and
silver sulfadiazine), which work by generating a bactericidal
level of silver ions. (The ions are released into aqueous
solution either by silver oxide or  dissolution of the silver salt.)
This new antimicrobial agent can be applied to animate
and inanimate surfaces by dipping, brushing, or spraying
without prior surface treatment. The coating does not
undergo photoreduction, degradation, or color change when
exposed to intense UV irradiation (4 mW/cm2 for 2 hr). This
new antimicrobial agent has excellent adhesion to virtually
all substrates, is optically clear, and does not delaminate,
flake, or crack. Treated surfaces subjected to a wipe test
retained their antimicrobial efficacy (Table 3) (11).
Permanently treated surfaces remained chemically inert and
retained their biocidal activity after exposure to various
physical and chemical stresses such as temperature (tested
from –20°C to 130°C), solvents (alcohol), solutions with a pH
of 4 to 10, solutions of high ionic strength, and sterilization by
conventional methods (e.g., steam, ethylene oxide, gamma-
irradiation). The coating contains low levels of silver iodide
(approx. 10 µg/cm2 of coated surface), and coated surfaces are
resistant to biofilm formation. Surfacine does not cause
mammalian cell toxicity and passes the acute systemic
toxicity tests recommended by the U.S. Pharmacopeia (SP
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Table 4. Activity of performic acid against spore-forming bacteriaa
     Lot 1      Lot 2
Bacillus subtilisb 0/30 growth 0/30 growth
B. subtilisc 0/30 growth 0/30 growth
Clostridium sporogenesb 0/30 growth 0/30 growth
C. sporogenesc 0/30 growth 0/30 growth
aMethodology: AOAC Sporicidal Activity Test, 10-min exposure; 1800
± 500 ppm performic acid; hard water/aged starting solution at 44
±2°C.
bSilk sutures.
cPorcelain cylinders.
If novel surface treatments such as this product prove to
be effective in significantly reducing microbial contamina-
tion, are cost-effective, and have long-term residual activity,
they may be extremely useful in limiting transmission of
nosocomial pathogens. The antimicrobial activity of this
coating makes it potentially suitable for a wide range of
applications, including disinfection of surfaces, microporous
filters, and medical devices and use as a topical ointment or
hand antiseptic.
A New Disinfectant: Superoxidized Water
The concept of electrolyzing saline to create a disinfectant
is appealing because the basic materials, saline and
electricity, are cheap and the end product (water) is not
damaging to the environment. A commercial adaptation of
this process, Sterilox, is available in the United Kingdom. The
mode of action is not clear but probably relates to a mixture of
oxidizing species.  The main products are hypochlorous acid at
a concentration of approximately 144 mg/L and free chlorine
radicals. This disinfectant is generated at the point of use by
passing a saline solution over titanium-coated electrodes at 9
amps. The product generated has a pH of 5.0-6.5 and an
oxidation reduction potential of >950 mV. Equipment to
produce the product may be expensive because parameters
such as pH, current, and redox potential must be closely
monitored. The solution has been shown to be nontoxic to
biological tissues. Although the solution is claimed to be
noncorrosive and nondamaging to endoscopes, one flexible
endoscope manufacturer has voided the warranty on its
endoscopes because superoxidized water was used to disinfect
them (12).
The antimicrobial activity of this new sterilant has been
tested against bacteria, mycobacteria, viruses, fungi, and spores
(13-15). Recent data have shown that freshly generated
superoxidized water is rapidly effective (<2 minutes) in
achieving a 5-log10 reduction of pathogenic microorganisms
(Mycobacterium tuberculosis, M. chelonae, poliovirus, HIV,
MRSA,  Escherichia coli,  Candida albicans,  Enterococcus
faecalis, Pseudomonas aeruginosa) in the absence of organic
loading. However, the biocidal activity of this disinfectant
was substantially reduced in the presence of organic material
(5% horse serum) (14). Additional studies are needed to
determine if this solution may be used as an alternative to
other disinfectants.
Endoclens: A New Liquid
Chemical Sterilization System
A new automated endoscope-reprocessing system has
been submitted to FDA for clearance. The system is designed
to provide rapid, automated, point-of-use chemical steriliza-
tion of flexible endoscopes and consists of a computer-
controlled endoscope-reprocessing machine and a new,
proprietary liquid sterilant that uses performic acid. The
sterilant is produced, as needed by the machine, by automatic
mixing of the two component solutions of hydrogen peroxide
and formic acid. This sterilant is fast-acting against spore-
forming bacteria (Table 4). The system’s major features are an
automatic cleaning process, capability to process two flexible
scopes asynchronously, automated channel blockage and leak
detection, filter water rinsing and scope drying after
sterilization, hard-copy documentation of key process
parameters, user-friendly machine interface, and total cycle
time less than 30 minutes. The reprocessor can also be
disinfected automatically to prevent infection or
pseudoinfection.
The reprocessor can independently process two endoscopes
at the user’s discretion since it has two washing/sterilization
bays. The endoscopes are attached to special holders (racks),
which slide into the machine bays located in the front of the
machine and  provide a connection between the reprocessor
and the endoscope’s inner channels. The endoscope racks are
designed to accommodate all types of flexible endoscopes.
During washing, enzymatic detergent is automatically
dispensed, diluted with warm water (45oC), and sprayed onto
the exterior endoscope surfaces and pumped through the
endoscope lumens. The enzymatic detergent is pumped
through the lumens with alternating pulses of compressed air
to assist in removing any adhering material.  Cleaning
studies performed by the manufacturer using a synthetic soil
show the system can satisfactorily clean and rinse detergents
from an endoscope in preparation for point-of-use steriliza-
tion.
The concentration and temperature of the mixed
chemicals are automatically measured by the machine with
refraction and temperature sensors. Once pumped into the
washing/sterilization bay, the sterilant is vigorously sprayed
over all exterior endoscope surfaces and pumped through all
endoscope lumens to sterilize the scope. Simulated-use
studies with resistant spores suspended in 5% serum and
inoculated on scope surfaces and inside lumens have
demonstrated the effectiveness of the sterilant.
All water used for washing/sterilization and rinsing is
filtered through a 0.2-µm filter. The scopes are dried when the
cycle is completed by using filtered compressed air that is
sprayed over the exterior scope surfaces and through the
interior lumens through the same connections used for the
washing and sterilization steps.
The total cycle time for scope testing, washing,
sterilization, and drying is less than 30 minutes. Upon
completion of each cycle, the reprocessor prints a hard-copy
record as well as retaining a record in memory, accessible
through its floppy disk drive. Printer parameters are printed
at the completion of each cycle and include scope
identification, processing date, key cycle parameters, space
for insertion of patient name or identification number,
procedure type, and date (16; CG Roberts, pers. commun.,
2000).
Attest Ethylene Oxide (EO) Rapid Readout
EO has been widely used as a low-temperature sterilant
since the 1950s. It is the most commonly used process for
sterilizing temperature- and moisture-sensitive medical
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Table 5. Sensitivity of Attest rapid readout ethylene oxide biological
indicator
 Incu-     No. False-
bation  growth  nega- Sensi-
 temp.   No. positives  tives tivity
Sterilization process   (°C) tested (168 hr) (4 hr) (4 hr)
37°C 600 mg EO/L, 37 1,100 752 0 100%
  60% relative humidity
54°C 600 mg EO/L, 37 1,300 842 0 100%
  60% relative humidity
Table 6. Comparative evaluation of sporicidal activity of new low-
temperature sterilization technologies (21,22)
Units positive/units tested
Sterilization LTU,a  LTU  LTU  SL,b
method 3 mm 2 mm 1 mm 3 mm
EO-HCFC 0/50 0/40 0/40 0/50
Sterrad 100S 0/50 0/40 0/40 0/40
Sterrad 50 0/30 0/30 0/30 0/30
Sterrad 100 2/40 3/40 37/50 0/40
aLTU = lumen test unit.
BSL = straight lumen.
December 1995, EO sterilizers were combined with a
chlorofluorocarbon stabilizing agent, but these agents were
phased out because they were linked to destruction of the
earth’s ozone layer. Alternative technologies currently
available and cleared by FDA include 100% EO and EO with
different stabilizing gases, such as carbon dioxide (CO2) or
hydrochlorofluorocarbon (17). A new rapid readout EO
biological indicator, designed for rapid and reliable
monitoring of EO sterilization processes, is available outside
the United States but has not yet been cleared by FDA.
Sterilization (the complete elimination or destruction of
all forms of microbial life) is recommended for all “critical”
medical items, such as surgical instruments, cardiac and
urinary catheters, implantable devices (e.g., heart valves),
and needles. Because it is essential to ensure sterilization of
critical items, monitoring of the sterilization process is
advised. Monitors may be mechanical, chemical, or biological.
Biological monitors are recommended because, unlike
chemical indicators, they measure the sterilization process
directly by using the most resistant microorganism (e.g.,
B. subtilis), not by merely testing the physical and chemical
conditions necessary for sterilization (18,19).
The new rapid readout EO biological indicator will
indicate an EO sterilization process failure by producing a
fluorescent change, which is detected in an auto-reader
within 4 hours of incubation at 37oC, and a visual pH color
change of the growth media within 96 hours of continued
incubation. The rapid readout EO biological indicator detects
the presence of B. subtilis by detecting the activity of an
enzyme present within the B. subtilis organism, beta-
glucosidase. The fluorescence indicates the presence of active
spore-associated enzyme and a sterilization process failure.
The rapid readout EO biological indicator also detects acid
metabolites produced during growth of the B. subtilis spore.
The acid metabolites are the result of a series of enzyme-
catalyzed reactions that occur during spore growth. The
growth produces a pH change in the medium that causes the
medium to change color from green to yellow, indicating an
EO sterilization process failure.
For hospital use, a monitor should be easy to use,
inexpensive, and not subject to exogenous contamination;
provide positive results as soon as possible after the cycle so
that corrective action may be taken; and provide positive
results only when the sterilization parameters (e.g., EO
concentration, humidity, time, temperature) are adequate to
kill microbial contaminants. However, the biological
indicator should not be so resistant that it causes needless
recall and overprocessing (18). The rapid readout EO
biological indicator has potential for substantially improving
assessment of EO cycles. According to  manufacturer’s data,
the enzyme was always detected whenever viable spores were
present. This was expected because the enzyme is relatively
EO resistant and is inactivated at a slightly longer exposure
time than the spore.
The rapid readout EO biological indicator can be used to
monitor 100% EO, EO-chlorofluorocarbons, and EO-hydro-
chlorofluorocarbon mixture sterilization cycles. It has not
been tested in EO-CO2 mixture sterilization cycles. The self-
contained design (i.e., it contains both the spore strip and
growth media) of the indicator makes it easy to use in the
department where the sterilizer is located. The rapid readout EO
biological indicator should be placed in a test pack (e.g., the
Association for the Advancement of Medical Instrumentation)
and placed in a full sterilizer load in the most challenging
area for the sterilizer (for EO placement should be in the
center). Data show that the 4-hour fluorescent sensitivity of
this indicator is > 97%, on the basis of the number of visual
growth-positive indicators after 168 hours (7 days) of
incubation at 37oC. In fact, all the 7-day growth-positive
indicators were detected by fluorescence within 4 hours of
incubation (Table 5), indicating that if there is no fluorescence
at 4 hours, no growth-positive indicators will be detected with
continued incubation.
The ability to monitor EO cycles in a surgical suite or
central processing and to have results in 4 hours should
enable operating room staff to intercept improperly sterilized
items either before use or before a surgery ends. If a hospital
could quarantine the load for the 4-hour readout, the need for
recalls of potentially nonsterile packages and for informing
physicians about the use of nonsterile medical devices could
be eliminated. New indicator technologies such as the rapid
readout EO biological indicators are likely to improve patient
safety (20, PM Schneider, pers. commun., 2000).
A New Low-Temperature Sterilization
Technology: Hydrogen Peroxide Plasma
Alternative technologies to sterilize temperature-
sensitive equipment are being developed. A new hydrogen
peroxide plasma sterilizer, the Sterrad 50, was recently
cleared by FDA. It is a smaller version (44-L sterilization
chamber) of the Sterrad 100 (73-L sterilization chamber),
cleared in 1991. The Sterrad 50 contains a single shelf for
placement of instruments to be sterilized within a
rectangular chamber, whereas the Sterrad 100 has two
shelves and a cylindrical chamber. The operational design of
the two sterilizers is similar except that the Sterrad 50
consists of two hydrogen peroxide vapor-diffusion stage-
plasma cycles. The sterilization cycles of the Sterrad 50 and
Sterrad 100 are 45 minutes and 72 minutes, respectively.
The Sterrad 50 was equally as effective as EO in killing
approximately 106 B. stearothermophilus spores present in
the center of narrow-lumen stainless steel tubes (Table 6).352 Emerging Infectious Diseases Vol. 7, No. 2, March–April 2001
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The Sterrad 50 and EO sterilized the carriers in even the
smallest-lumened device, which was 1 mm in diameter (21).
Conclusions
New sterilization and disinfection technologies may
provide significant advantages over existing technologies
(Table 7).  However, data currently available have primarily
been generated by the manufacturers and need to be
independently validated. If these new technologies are
demonstrated to be effective, their cost-effectiveness compared
with standard technologies should be assessed. These new
technologies hold the promise of improved patient care.
Dr. Rutala is director of the Hospital Epidemiology, Occupational
Health and Safety Program at the University of North Carolina (UNC)
Health Care System and professor of medicine at UNC School of Medi-
cine, Chapel Hill, NC. His research interests include prevention of noso-
comial infections, disinfection, and sterilization.
Dr. Weber is medical director of the Hospital Epidemiology, Occu-
pational Health and Safety Program at UNC Health Care System and
professor of medicine, epidemiology, and pediatrics at the UNC Schools
of Medicine and Public Health. His research interests include preven-
tion of nosocomial infections, disinfection, and sterilization.
Table 7. Comparison of new and standard disinfection and sterilization technologies
   Technology Comparison of new with standard technology
New Standard Advantages Disadvantages Future needs
OPA Glutaraldehyde -Shorter process time (12 vs. 45 min) -Stains protein gray -Additional studies of
-No activation -Higher cost     antimicrobial efficacy
-Not a known irritant to eyes -Cost-effectiveness study
    and nasal passages -Study of effectiveness in
-No vapor ceiling limit     actual clinical use
-Weak odor -Verification of more cycles
per solution than glutaraldehyde
Surfacine Disinfectants (phenolics -Antimicrobial persistence -Cost? -Assess microbicidal activity against
  quaternary ammonium);     (>13 days)     broad spectrum of pathogens
Antiseptics (alcohol, -May be used on animate and -Demonstration of efficacy to reduce
  iodophor, chlorhexidine     inanimate surfaces     nosocomial infections
  gluconate) -Broad antimicrobial spectrum -Human safety and toxicity data
-Transfers active agent (silver)     for use as  an antiseptic
    to microbes on demand -Demonstrate antimicrobial
    without elution     activity in presence of
-Resistant to forming biofilm     organic matter
-No toxicity to mammalian cells
Super- High- or low-level -Basic materials (saline and -Production equipment expensive -Evaluation of endoscope
  oxidized   disinfectants;     electricity) inexpensive     due to monitoring     compatibility
  water   antiseptics -End product not damaging -Endoscope compatibility unknown -Cost-effectiveness study
    to environment -Decreased efficacy in presence of
-Nontoxic to biological tissues     organic matter
-Limited-use life (must be freshly
    generated)
Endoclens None -Device automatically cleans -Cost? -Cost-effectiveness study
    and sterilizes -Used for immersible instru- -Study of effectiveness in actual
-Rapid cycle time (<30 min)     ments only     clinical use
-Tests endoscope for channel -Point-of-use system, no -Assessment of microbicidal
    blockage and leaks     long-term storage     activity
-Advantages of automated process
    (e.g.,  consistent exposure to
    sterilant, filtered water rinse,
    operator convenience)
EO rapid 48-hr spore readout -Rapid (4-hr), reliable assessment -Cost? -Cost-effectiveness  study
  readout   biological indicator     of sterilization efficacy -Not tested with EO -Validation of claimed
-Prevents recall of released     and CO2 mixtures     100% sensitivity
    sterilization loads
Plasma Hydrogen peroxide gas -Use of two hydrogen peroxide -Cost? -Cost-effectiveness study
  sterilizer   plasma sterilizer     diffusion-plasma stage -Endoscopes with lengths -Study of effectiveness in actual
    cycles is a more effective     >40 cm or a diameter of     clinical use
     sterilization process     <3 mm cannot be processed
-Reduced cycle time (45 min)
-Various sized units available
-Leaves no toxic residues353 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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